Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)

atrickpay

atrickpay
5 Followers
4 Following
Send Message
View as an RSS Feed
View atrickpay's Comments BY TICKER:
Latest  |  Highest rated
  • OncoSec's And Ziopharm's IL-12 Targeted Delivery Systems: Which Will Succeed? [View article]
    So you think the phase 2 data that is pending will be a failure?
    Jun 13 02:34 PM | 0 Likes Like |Link to Comment
  • OncoSec's And Ziopharm's IL-12 Targeted Delivery Systems: Which Will Succeed? [View article]
    Why mite you initiate a short in ziop if there is data pending in the coming days? if it's good, you mite lose, if it's bad, you'd likely win,,,
    Jun 12 12:19 PM | 0 Likes Like |Link to Comment
  • 6 New Bearish Celsion Myths Destroyed [View article]
    There were no warrants in the 5.31.13 announced financing:
    http://bit.ly/13BSDAm. So the 6.264492m shares purchasable on conversoin of such warrants stem from an earlier financing. Which 1? And What's the exercise price on them? If their exercise on them is so out of the money, it wouldn't matter much to them.
    Jun 12 10:03 AM | 0 Likes Like |Link to Comment
  • 3 Bullish Clues Celsion's Financing Gives Us [View article]
    ya, here's the link to the study details: http://1.usa.gov/11taJ4g

    Estimated study completion date is showing as Nov. 2014. So i think that Quoth simply has made an error, and has gotten this wrong. And furthermore, I hadn't seen anywhere else that CLSN was supposed to have any data pending (besides the release of the sub group >45m RFA at the conference June 19-20)
    Jun 9 04:59 PM | 1 Like Like |Link to Comment
  • 3 Bullish Clues Celsion's Financing Gives Us [View article]
    Could simply be an error. Where is quoth getting his evidence that it's any day now?
    Jun 9 02:39 PM | 0 Likes Like |Link to Comment
  • Vanda Pharmaceuticals: A Small-Cap Biotech With A Pipeline Allowing For Long-Term Growth [View article]
    ya, i guess it was because of the positive phase 3 results for tamiselteon. I guess as well that prior to them coming out, the consensus mite have been that it would fail its trial
    Jun 7 05:37 PM | 0 Likes Like |Link to Comment
  • Vanda Pharmaceuticals: A Small-Cap Biotech With A Pipeline Allowing For Long-Term Growth [View article]
    how come this company was trading below 3$ share in november 2012? It had a negative enterprise value at that time. Now the share price is up 3x (200%) going from 3 to 10
    Jun 6 02:00 PM | 0 Likes Like |Link to Comment
  • Blast Off Time For Unilife [View article]
    unis used the atm on 5.29?? i thot they wern't go to sell new shares at all! (with the debt deal pending)!
    Jun 3 03:34 PM | 0 Likes Like |Link to Comment
  • 3 Bullish Clues Celsion's Financing Gives Us [View article]
    lol k
    May 31 11:50 AM | 0 Likes Like |Link to Comment
  • 3 Bullish Clues Celsion's Financing Gives Us [View article]
    how'd you get this article published so quickly? i've seen it take days for ppl to their article published by s.a.
    May 31 11:44 AM | 1 Like Like |Link to Comment
  • What Is So Exciting About MEI Pharma? [View article]
    article didn't mention the market cap of the company once. Pretty key thing to determine if we think it's overvalued or not?
    May 29 12:46 PM | 0 Likes Like |Link to Comment
  • These 2 Patents Could Mean Everything Or Nothing [View article]
    quoth: how did you get this article approved so quickly and published? i know some people where they submit an article and it takes several days. Did some guy at s.a. just want this one publish really quickly?
    May 22 12:06 PM | 1 Like Like |Link to Comment
  • But, But BlackBerry Was Dead [View article]
    what is the source of the 6% and 13.5% figures? No sources given lol. Even at the source article for this, doesn't give the source of these q4 and q1's lol.
    May 17 03:16 PM | 1 Like Like |Link to Comment
  • Emerging Biomarker Companies Redux: Positioned For Growth [View article]
    Before the financing last week, VRML has 15.2m shares o/s. Using a s.p. of $1.46 gave it a cap of $22.19m. It's current cap of $91.03m divided by $22.19m is a 4.10x increase. In one week (!).
    May 15 03:49 PM | 0 Likes Like |Link to Comment
  • Emerging Biomarker Companies Redux: Positioned For Growth [View article]
    VRml has 15.2m shares o/s + 20.5m from the financing...so 35.7m in total...so it's worth $91.03m at $2.55/share
    May 15 03:45 PM | 0 Likes Like |Link to Comment
COMMENTS STATS
237 Comments
59 Likes